TapewireFind a company

person · Reporting owner

Gaiero David G

Disclosed activity across 4 companies

Tapewire entity
90124
SEC CIK
0001799784

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Cyteir Therapeutics, Inc.CYT · Entity 92707Chief Financial OfficerFebruary 29, 2024March 05, 2024
Faeth Therapeutics, Inc.SNSE · Entity 5029Principal Financial OfficerMay 10, 2024May 16, 2024
Imunon, Inc.IMNN · Entity 8041Chief Financial OfficerJune 01, 2024June 10, 2024
Wave Life Sciences, Inc.WVE · Entity 4976Interim CFOMarch 03, 2020March 05, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cyteir Therapeutics, Inc.

Report date February 29, 2024 · Filed March 05, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect102,391 Ending reported balance After 2024-03-04 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2024-02-29 · Exercise / conversion · Acquired 3,239 · Balance 95,272

Row 2 · 2024-02-29 · Exercise / conversion · Acquired 4,746 · Balance 100,018

Row 3 · 2024-03-04 · Exercise / conversion · Acquired 2,373 · Balance 102,391

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2030-12-10Direct16,196 Reported balance After 2024-02-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-02-29 · Exercise / conversion · Disposed 3,239 · Balance 16,196

F1: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03Direct85,425 Reported balance After 2024-02-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-02-29 · Exercise / conversion · Disposed 4,746 · Balance 85,425

F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03Direct83,052 Reported balance After 2024-03-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-03-04 · Exercise / conversion · Disposed 2,373 · Balance 83,052

F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Faeth Therapeutics, Inc.

Report date May 10, 2024 · Filed May 16, 2024

This filing explicitly reported no securities owned.

Imunon, Inc.

Report date June 01, 2024 · Filed June 10, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance Holding disclosure · report date 2024-06-01 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 0

Wave Life Sciences, Inc.

Report date March 03, 2020 · Filed March 05, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2030-03-03Direct18,000 Reported balance After 2020-03-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-03-03 · Grant · Acquired 18,000 · Balance 18,000

F1: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 04, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 2,373 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 6

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,052

Underlying: Common Stock · 2,373 shares

Expires 2033-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 2,373 $1.69 $4,010.37
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 3

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 29, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 4,746 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 5

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,425

Underlying: Common Stock · 4,746 shares

Expires 2033-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
February 29, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 3,239 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 4

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,196

Underlying: Common Stock · 3,239 shares

Expires 2030-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
February 29, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 4,746 $1.69 $8,020.74
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 2

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 29, 2024 Filed Mar 5, 2024 18:11 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 3,239 $1.68 $5,441.52
Disclosure

SEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2023 Filed Dec 14, 2023 16:00 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 2,373 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-23-058610 · doc4.xml · derivative · entry 4

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,171

Underlying: Common Stock · 2,373 shares

Expires 2033-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
December 11, 2023 Filed Dec 14, 2023 16:00 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 1,620 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001209191-23-058610 · doc4.xml · derivative · entry 3

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,435

Underlying: Common Stock · 1,620 shares

Expires 2030-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
December 11, 2023 Filed Dec 14, 2023 16:00 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 2,373 $1.69 $4,010.37
Disclosure

SEC source: 0001209191-23-058610 · doc4.xml · nonDerivative · entry 2

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 11, 2023 Filed Dec 14, 2023 16:00 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 1,620 $1.68 $2,721.60
Disclosure

SEC source: 0001209191-23-058610 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 13:47 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 21,356 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-23-056425 · doc4.xml · derivative · entry 4

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,544

Underlying: Common Stock · 21,356 shares

Expires 2033-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 13:47 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 52,584 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001209191-23-056425 · doc4.xml · derivative · entry 3

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,055

Underlying: Common Stock · 52,584 shares

Expires 2030-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 13:47 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 21,356 $1.69 $36,091.64
Disclosure

SEC source: 0001209191-23-056425 · doc4.xml · nonDerivative · entry 2

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023.

Read SEC document
November 20, 2023 Filed Nov 22, 2023 13:47 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 52,584 $1.68 $88,341.12
Disclosure

SEC source: 0001209191-23-056425 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 03, 2023 Filed Feb 7, 2023 16:41 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 GrantStock Option (Right to Buy) · Derivative 113,900 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-23-007536 · doc4.xml · derivative · entry 2

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,900

Underlying: Common Stock · 113,900 shares

Expires 2033-02-03

F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

Read SEC document
January 13, 2023 Filed Feb 7, 2023 16:41 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 GrantCommon Stock 5,000 $1.49 $7,450.00
Disclosure

SEC source: 0001209191-23-007536 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

F1 · kind: The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period.

Read SEC document
February 22, 2022 Filed Feb 24, 2022 16:54 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 GrantStock Option (Right to Buy) · Derivative 23,000 $0.00 Strike: $5.96 $0.00
Disclosure

SEC source: 0000899243-22-007631 · doc4.xml · derivative · entry 1

Gaiero David G · CIK 0001799784 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

Read SEC document
December 20, 2021 Filed Feb 7, 2023 16:38 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionStock Option (Right to Buy) · Derivative 4,100 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001209191-23-007528 · doc4.xml · derivative · entry 2

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,639

Underlying: Common Stock · 4,100 shares

Expires 2030-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4.

F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Read SEC document
December 20, 2021 Filed Feb 7, 2023 16:38 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 Exercise / conversionCommon Stock 4,100 $1.68 $6,888.00
Disclosure

SEC source: 0001209191-23-007528 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4.

Read SEC document
March 03, 2020 Filed Mar 5, 2020 20:48 UTC Wave Life Sciences, Inc. WVE · Entity 4976 GrantShare Option (right to buy) · Derivative 18,000 $0.00 Strike: $8.17 $0.00
Disclosure

SEC source: 0000899243-20-007284 · doc4.xml · derivative · entry 1

Gaiero David G · CIK 0001799784 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Ordinary Shares · 18,000 shares

Expires 2030-03-03

F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 18:16 UTC Wave Life Sciences, Inc. WVE · Entity 4976 SaleOrdinary Shares 651 $7.00 $4,557.00
Disclosure

SEC source: 0000899243-20-003379 · doc4.xml · nonDerivative · entry 1

Gaiero David G · CIK 0001799784 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,392

F1 · kind: On February 3, 2020, the reporting person sold 651 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 1, 2020. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.00 to $7.049 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.